Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp demonstrated robust financial performance, with its burn care franchise experiencing a 22% year-over-year growth, reaching $39.9 million in FY2024, reflecting effective salesforce expansion which is anticipated to continue driving high-single-digit growth into 2025. The company's MACI product also showed significant momentum, reporting a notable 21% year-over-year growth to $68.3 million in the fourth quarter of 2024, supported by a three-year compound annual growth rate (CAGR) of 20.9% and promising new product launches. Moreover, guidance indicates a strong gross margin of approximately 73-74%, and projected revenue growth between 20-23% for 2025, suggesting a potential inflection point for profitability that could positively influence investor sentiment.

Bears say

Vericel Corp's negative outlook is primarily underscored by a series of recent performance misses and emerging concerns regarding its growth trajectory. The reported revenue of $75.4 million in the fourth quarter fell short of earlier expectations, particularly driven by underperformance in key products like Epicel and NexoBrid, with management citing patient health issues and fewer grafts per patient as contributing factors. Additionally, the risks associated with market dynamics, potential recession impacts, and the delayed uptake of newer therapies further exacerbate the uncertainty surrounding the company's financial stability and growth prospects.

Vericel (VCEL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.